A cohort study measuring SARS-CoV-2 seroconversion and serial viral testing in university students

[1]  Amanda M Jovaag,et al.  Interventions to Disrupt Coronavirus Disease Transmission at a University, Wisconsin, USA, August–October 2020 , 2021, Emerging infectious diseases.

[2]  P. Remington,et al.  Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Presence of Anti–SARS-CoV-2 Antibodies Among University Student Dormitory Residents, September–November 2020 , 2021, Open forum infectious diseases.

[3]  J. Rassen,et al.  Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection , 2021, JAMA internal medicine.

[4]  R. Westergaard,et al.  Trends in Outbreak-Associated Cases of COVID-19 — Wisconsin, March–November 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[5]  Krista K. Proia,et al.  COVID-19 Trends Among Persons Aged 0–24 Years — United States, March 1–December 12, 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[6]  M. Nussenzweig,et al.  Evolution of antibody immunity to SARS-CoV-2 , 2021, Nature.

[7]  A. Sette,et al.  Adaptive immunity to SARS-CoV-2 and COVID-19 , 2021, Cell.

[8]  V. Allen,et al.  SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline. , 2021, The Journal of infectious diseases.

[9]  M. Killerby,et al.  Performance of an Antigen-Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses — Wisconsin, September–October 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[10]  D. Stuart,et al.  Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers , 2020, The New England journal of medicine.

[11]  R. Tibshirani,et al.  Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome , 2020, Science Immunology.

[12]  R. Hasnain-Wynia,et al.  Disproportionate Incidence of COVID-19 Infection, Hospitalizations, and Deaths Among Persons Identifying as Hispanic or Latino — Denver, Colorado March–October 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[13]  Samuel M. Brown,et al.  Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network — 12 States, April–August 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[14]  Z. Livneh,et al.  Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation , 2020, EClinicalMedicine.

[15]  L. Grohskopf,et al.  Lack of antibodies to SARS-CoV-2 in a large cohort of previously infected persons , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  B. Wolff,et al.  COVID-19 Mitigation Behaviors by Age Group — United States, April–June 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[17]  C. Cordon-Cardo,et al.  Robust neutralizing antibodies to SARS-CoV-2 infection persist for months , 2020, Science.

[18]  M. Malim,et al.  Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans , 2020, Nature Microbiology.

[19]  P. G. Choe,et al.  Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection , 2020, Emerging infectious diseases.

[20]  B. Zhang,et al.  Antibody dynamics to SARS‐CoV‐2 in asymptomatic COVID‐19 infections , 2020, Allergy.

[21]  G. Rodger,et al.  Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison , 2020, The Lancet Infectious Diseases.

[22]  D. Cummings,et al.  A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity , 2020, Nature Communications.

[23]  C. Blackmore,et al.  Disparities in Incidence of COVID-19 Among Underrepresented Racial/Ethnic Groups in Counties Identified as Hotspots During June 5–18, 2020 — 22 States, February–June 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[24]  Otto O. Yang,et al.  Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19 , 2020, The New England journal of medicine.

[25]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[26]  Harnish Mukesh Naik,et al.  Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population , 2020, medRxiv.

[27]  S. Lee,et al.  Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients , 2020, Emerging infectious diseases.

[28]  Y. Tie,et al.  Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[29]  P. Tambyah,et al.  Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection , 2020, Clinical Microbiology and Infection.

[30]  G. Alter,et al.  Dissecting antibody-mediated protection against SARS-CoV-2 , 2020, Nature Reviews Immunology.

[31]  R. Davey,et al.  Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019 , 2020, The Journal of Infectious Diseases.

[32]  Anna María Nápoles,et al.  COVID-19 and Racial/Ethnic Disparities. , 2020, JAMA.

[33]  Jun Yuan,et al.  Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.

[34]  Lei Liu,et al.  Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  J. Adams.  Institutions of higher education , 2019, Emerging Voices in Natural Hazards Research.

[36]  Publisher's Note , 2018, Anaesthesia.